Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.

The Journal of infectious diseases (2004-08-06)

John P DeVincenzo, Caroline B Hall, David W Kimberlin, Pablo J Sánchez, William J Rodriguez, Barbara A Jantausch, Lawrence Corey, Jeffrey S Kahn, Janet A Englund, JoAnn A Suzich, Frances J Palmer-Hill, Luis Branco, Syd Johnson, Nita K Patel, Franco M Piazza

PMID15295704

ABSTRACT

Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.

MATERIALS

Product Number

Brand

Product Description

MAB858-4

Sigma-Aldrich

Anti-RSV Antibody, blend, clones 133-1H, 131-2G, and 130-12H, ascites fluid, Chemicon^®, from mouse